Quest Diagnostics Inc (DGX) Stock AnalysisDGXQuest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. It provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and its connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. Its other customers include health plans, employers, emerging retail healthcare providers, government agencies, and others. Its services are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Quest Diagnostics Inc is currently priced at $235, with a forward P/E ratio of 19.53, indicating reasonable valuation compared to its growth potential. However, the company faces a significant risk with the upcoming 15% cut in lab reimbursement rates by CMS, which could impact approximately 11% of its revenue. While the stock has shown a strong year-to-date change of +35.22%, the recent insider activity is neutral, and the stock's recent performance has been mixed, making it prudent to hold rather than buy at this moment.

20 analysts cover DGX: 5 rate it Buy, 14 Hold and 1 Sell. The average price target is 203.33.